Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CareDx, Inc.CDNA · Entity 4344 | Director | July 07, 2025 | July 10, 2025 |
| Kyverna Therapeutics, Inc.KYTX · Entity 5452 | Director · Chief Executive Officer | February 07, 2024 | February 08, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CareDx, Inc.
Report date July 07, 2025 · Filed July 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 308,846 |
Reported balance
After 2025-07-07 transaction · row 1
1 source rowRow 1 · 2025-07-07 · Sale · Disposed 10,000 · Balance 308,846 F1: The transaction reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the Reporting Person on August 21, 2024. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.40 to $18.86 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the Reporting Person on August 21, 2024.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.40 to $18.86 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Kyverna Therapeutics, Inc.
Report date February 07, 2024 · Filed February 08, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,220 |
Reported balance
Holding disclosure · report date 2024-02-07 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 58,220 |
| Common StockSEC Table I · non-derivative | IndirectBy The Maag Family Irrevocable Trust | 349,321 |
Reported balance
Holding disclosure · report date 2024-02-07 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 349,321 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.83 · Expires 2033-11-05 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-02-07 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F1: 25% of the original number of shares subject to the option shall vest on January 1, 2025, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.33 · Expires 2033-07-12 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-02-07 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F2: 25% of the original number of shares subject to the option shall vest on July 1, 2024, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.15 · Expires 2032-11-21 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-02-07 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F3: 25% of the original number of shares subject to the option vested on October 13, 2023, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the original number of shares subject to the option shall vest on January 1, 2025, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
F2: 25% of the original number of shares subject to the option shall vest on July 1, 2024, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
F3: 25% of the original number of shares subject to the option vested on October 13, 2023, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Miromatrix Medical Inc.
Report date December 12, 2023 · Filed December 13, 2023
Section 16 reporting ended · disclosed 2023-12-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,368 |
Reported balance
After 2023-12-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-12-12 · Other · Disposed 62,092 · Balance 58,368 F1: Shares tendered and accepted pursuant to the terms of an offer conducted pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, United Therapeutics Corporation ("Parent") and Morpheus Subsidiary Inc., dated as of October 29, 2023, for consideration consisting of (i) $3.25 per share, payable in cash, without interest and less any required withholding taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR"). F2: Each CVR entitles the reporting person to potentially receive contingent payments of up to an aggregate of $1.75 per CVR, without interest and less any required withholding taxes, upon the achievement of a specified milestone in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement"), dated as of December 12, 2023, by and between Parent and Continental Stock Transfer & Trust Company. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-12-13 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-12-13 · Disposition to issuer · Disposed 58,368 · Balance 0 F3: Previously unvested restricted stock units ("RSUs"), each of which represented a contingent right to receive one share of the Issuer's common stock. F4: In connection with the closing under the Merger Agreement, each outstanding RSU award was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to the RSU award multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such RSU award. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares tendered and accepted pursuant to the terms of an offer conducted pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, United Therapeutics Corporation ("Parent") and Morpheus Subsidiary Inc., dated as of October 29, 2023, for consideration consisting of (i) $3.25 per share, payable in cash, without interest and less any required withholding taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR").
F2: Each CVR entitles the reporting person to potentially receive contingent payments of up to an aggregate of $1.75 per CVR, without interest and less any required withholding taxes, upon the achievement of a specified milestone in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement"), dated as of December 12, 2023, by and between Parent and Continental Stock Transfer & Trust Company.
F3: Previously unvested restricted stock units ("RSUs"), each of which represented a contingent right to receive one share of the Issuer's common stock.
F4: In connection with the closing under the Merger Agreement, each outstanding RSU award was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to the RSU award multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such RSU award.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 10, 2021 Filed May 12, 2021 22:53 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 14,872 | $12.24 Strike: $12.24 | $182,033.28 |
DisclosureSEC source: 0001217234-21-000099 · wf-form4_162085998376348.xml · derivative · entry 16 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,753 Underlying: Common Stock · 14,872 shares Expires 2028-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: 1/4th of the shares subject to the option vested on June 1, 2019 and 1/48th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| May 10, 2021 Filed May 12, 2021 22:53 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 8,108 | $6.31 Strike: $6.31 | $51,161.48 |
DisclosureSEC source: 0001217234-21-000099 · wf-form4_162085998376348.xml · derivative · entry 15 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,032 Underlying: Common Stock · 8,108 shares Expires 2028-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: 1/4th of the shares subject to the option vested on January 19, 2019 and 1/48th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| May 10, 2021 Filed May 12, 2021 22:53 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,313 | $5.90 Strike: $5.90 | $19,546.70 |
DisclosureSEC source: 0001217234-21-000099 · wf-form4_162085998376348.xml · derivative · entry 14 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,312 Underlying: Common Stock · 3,313 shares Expires 2027-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: 25% of the shares subject to the option vested on October 20, 2018 and 1/48th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| May 10, 2021 Filed May 12, 2021 22:53 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 15,692 | $70.36 | $1,104,087.55 |
DisclosureSEC source: 0001217234-21-000099 · wf-form4_162085998376348.xml · nonDerivative · entry 6 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,444 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.67 to $70.515, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| May 10, 2021 Filed May 12, 2021 22:53 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 317 | $68.61 | $21,749.72 |
DisclosureSEC source: 0001217234-21-000099 · wf-form4_162085998376348.xml · nonDerivative · entry 5 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,136 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.02 to $68.85, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| May 10, 2021 Filed May 12, 2021 22:53 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 10,284 | $66.78 | $686,786.09 |
DisclosureSEC source: 0001217234-21-000099 · wf-form4_162085998376348.xml · nonDerivative · entry 4 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,453 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.455 to $67.28, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| May 10, 2021 Filed May 12, 2021 22:53 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 14,872 | $12.24 | $182,033.28 |
DisclosureSEC source: 0001217234-21-000099 · wf-form4_162085998376348.xml · nonDerivative · entry 3 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 435,737 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2021 Filed May 12, 2021 22:53 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 8,108 | $6.31 | $51,161.48 |
DisclosureSEC source: 0001217234-21-000099 · wf-form4_162085998376348.xml · nonDerivative · entry 2 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420,865 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2021 Filed May 12, 2021 22:53 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 3,313 | $5.90 | $19,546.70 |
DisclosureSEC source: 0001217234-21-000099 · wf-form4_162085998376348.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412,757 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2021 Filed May 7, 2021 00:55 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $27.17 | $0.00 |
DisclosureSEC source: 0001217234-21-000097 · wf-form4_162034892401928.xml · derivative · entry 7 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,899 Underlying: Common Stock · 10,000 shares Expires 2029-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2020. F6 · derivative.exercise_date: 1/4th of the shares subject to the option vested on January 25, 2020 and 1/48th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| May 05, 2021 Filed May 7, 2021 00:55 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 2,262 | $74.31 | $168,087.86 |
DisclosureSEC source: 0001217234-21-000097 · wf-form4_162034892401928.xml · nonDerivative · entry 4 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,444 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.98 to $74.75, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| May 05, 2021 Filed May 7, 2021 00:55 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 3,528 | $73.53 | $259,422.66 |
DisclosureSEC source: 0001217234-21-000097 · wf-form4_162034892401928.xml · nonDerivative · entry 3 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 411,706 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.97 to $73.92, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| May 05, 2021 Filed May 7, 2021 00:55 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 4,210 | $72.61 | $305,681.36 |
DisclosureSEC source: 0001217234-21-000097 · wf-form4_162034892401928.xml · nonDerivative · entry 2 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 415,234 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.94 to $72.925, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| May 05, 2021 Filed May 7, 2021 00:55 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 10,000 | $27.17 | $271,700.00 |
DisclosureSEC source: 0001217234-21-000097 · wf-form4_162034892401928.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 419,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2020. Read SEC document |
| May 03, 2021 Filed May 4, 2021 22:55 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 7,711 | $0.00 Strike: $27.17 | $0.00 |
DisclosureSEC source: 0001217234-21-000087 · wf-form4_162016890334863.xml · derivative · entry 8 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,289 Underlying: Common Stock · 7,711 shares Expires 2029-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2020. F6 · derivative.exercise_date: 1/4th of the shares subject to the option vested on January 25, 2020 and 1/48th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| May 03, 2021 Filed May 4, 2021 22:55 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 7,375 | $0.00 Strike: $12.24 | $0.00 |
DisclosureSEC source: 0001217234-21-000087 · wf-form4_162016890334863.xml · derivative · entry 7 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,625 Underlying: Common Stock · 7,375 shares Expires 2028-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2020. F5 · derivative.exercise_date: 1/4th of the shares subject to the option vested on June 1, 2019 and 1/48th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| May 03, 2021 Filed May 4, 2021 22:55 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 3,048 | $77.42 | $235,964.27 |
DisclosureSEC source: 0001217234-21-000087 · wf-form4_162016890334863.xml · nonDerivative · entry 4 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 408,054 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.02 to $77.83, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| May 03, 2021 Filed May 4, 2021 22:55 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 16,952 | $76.50 | $1,296,758.50 |
DisclosureSEC source: 0001217234-21-000087 · wf-form4_162016890334863.xml · nonDerivative · entry 3 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 411,102 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.005 to $77.00, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| May 03, 2021 Filed May 4, 2021 22:55 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 7,711 | $27.17 | $209,507.87 |
DisclosureSEC source: 0001217234-21-000087 · wf-form4_162016890334863.xml · nonDerivative · entry 2 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 428,054 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2020. Read SEC document |
| May 03, 2021 Filed May 4, 2021 22:55 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 7,375 | $12.24 | $90,270.00 |
DisclosureSEC source: 0001217234-21-000087 · wf-form4_162016890334863.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420,343 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2020. Read SEC document |
| May 03, 2021 Filed May 7, 2021 00:53 UTC Amendment | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 9,101 | $0.00 Strike: $27.17 | $0.00 |
DisclosureSEC source: 0001217234-21-000095 · wf-form4a_162034878244419.xml · derivative · entry 4 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,899 Underlying: Common Stock · 9,101 shares Expires 2029-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2020. F4 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on January 25, 2020 and 1/48th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| May 03, 2021 Filed May 7, 2021 00:53 UTC Amendment | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 3,048 | $77.42 | $235,964.27 |
DisclosureSEC source: 0001217234-21-000095 · wf-form4a_162034878244419.xml · nonDerivative · entry 3 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,444 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.02 to $77.83, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| May 03, 2021 Filed May 7, 2021 00:53 UTC Amendment | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 16,952 | $76.50 | $1,296,758.50 |
DisclosureSEC source: 0001217234-21-000095 · wf-form4a_162034878244419.xml · nonDerivative · entry 2 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412,492 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.005 to $77.00, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| May 03, 2021 Filed May 7, 2021 00:53 UTC Amendment | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 9,101 | $27.17 | $247,274.17 |
DisclosureSEC source: 0001217234-21-000095 · wf-form4a_162034878244419.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 429,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2020. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 20:29 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 3,800 | $72.90 | $277,013.16 |
DisclosureSEC source: 0001217234-21-000067 · wf-form4_161774089198210.xml · nonDerivative · entry 3 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412,968 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 5, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.74 to $73.20, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 20:29 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 4,700 | $72.40 | $340,282.82 |
DisclosureSEC source: 0001217234-21-000067 · wf-form4_161774089198210.xml · nonDerivative · entry 2 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416,768 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 5, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.74 to $72.71, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 20:29 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 1,500 | $71.15 | $106,719.45 |
DisclosureSEC source: 0001217234-21-000067 · wf-form4_161774089198210.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,468 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 5, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.72 to $71.56, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| March 05, 2021 Filed Mar 6, 2021 01:45 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 300 | $66.34 | $19,901.49 |
DisclosureSEC source: 0001217234-21-000055 · wf-form4_161499511161799.xml · nonDerivative · entry 9 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 422,968 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 5, 2020. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.11 to $66.46, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. F3 · balance_after: These shares remain subject to a lock-up agreement entered into among the Reporting Person and the representatives of the underwriters for the Issuer's public offering of common stock completed in January 2021. Read SEC document |
| March 05, 2021 Filed Mar 6, 2021 01:45 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 200 | $65.18 | $13,036.60 |
DisclosureSEC source: 0001217234-21-000055 · wf-form4_161499511161799.xml · nonDerivative · entry 8 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 423,268 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 5, 2020. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.05 to $65.31, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. F3 · balance_after: These shares remain subject to a lock-up agreement entered into among the Reporting Person and the representatives of the underwriters for the Issuer's public offering of common stock completed in January 2021. Read SEC document |
| March 05, 2021 Filed Mar 6, 2021 01:45 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 900 | $64.15 | $57,735.99 |
DisclosureSEC source: 0001217234-21-000055 · wf-form4_161499511161799.xml · nonDerivative · entry 7 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 423,468 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 5, 2020. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.75 to $64.53, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. F3 · balance_after: These shares remain subject to a lock-up agreement entered into among the Reporting Person and the representatives of the underwriters for the Issuer's public offering of common stock completed in January 2021. Read SEC document |
| March 05, 2021 Filed Mar 6, 2021 01:45 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 1,300 | $63.25 | $82,229.94 |
DisclosureSEC source: 0001217234-21-000055 · wf-form4_161499511161799.xml · nonDerivative · entry 6 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,368 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 5, 2020. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.72 to $63.60, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. F3 · balance_after: These shares remain subject to a lock-up agreement entered into among the Reporting Person and the representatives of the underwriters for the Issuer's public offering of common stock completed in January 2021. Read SEC document |
| March 05, 2021 Filed Mar 6, 2021 01:45 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 1,800 | $62.13 | $111,838.50 |
DisclosureSEC source: 0001217234-21-000055 · wf-form4_161499511161799.xml · nonDerivative · entry 5 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,668 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 5, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.67 to $62.57, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. F3 · balance_after: These shares remain subject to a lock-up agreement entered into among the Reporting Person and the representatives of the underwriters for the Issuer's public offering of common stock completed in January 2021. Read SEC document |
| March 05, 2021 Filed Mar 6, 2021 01:45 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 1,856 | $61.07 | $113,340.72 |
DisclosureSEC source: 0001217234-21-000055 · wf-form4_161499511161799.xml · nonDerivative · entry 4 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 427,468 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 5, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.61 to $61.59, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. F3 · balance_after: These shares remain subject to a lock-up agreement entered into among the Reporting Person and the representatives of the underwriters for the Issuer's public offering of common stock completed in January 2021. Read SEC document |
| March 05, 2021 Filed Mar 6, 2021 01:45 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 1,644 | $60.03 | $98,681.76 |
DisclosureSEC source: 0001217234-21-000055 · wf-form4_161499511161799.xml · nonDerivative · entry 3 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 429,324 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 5, 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.47 to $60.45, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. F3 · balance_after: These shares remain subject to a lock-up agreement entered into among the Reporting Person and the representatives of the underwriters for the Issuer's public offering of common stock completed in January 2021. Read SEC document |
| March 05, 2021 Filed Mar 6, 2021 01:45 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 800 | $58.71 | $46,967.04 |
DisclosureSEC source: 0001217234-21-000055 · wf-form4_161499511161799.xml · nonDerivative · entry 2 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,968 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 5, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.25 to $59.17, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. F3 · balance_after: These shares remain subject to a lock-up agreement entered into among the Reporting Person and the representatives of the underwriters for the Issuer's public offering of common stock completed in January 2021. Read SEC document |
| March 05, 2021 Filed Mar 6, 2021 01:45 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 1,200 | $57.60 | $69,119.52 |
DisclosureSEC source: 0001217234-21-000055 · wf-form4_161499511161799.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 431,768 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 5, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.14 to $57.99, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. F3 · balance_after: These shares remain subject to a lock-up agreement entered into among the Reporting Person and the representatives of the underwriters for the Issuer's public offering of common stock completed in January 2021. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:32 UTC | CareDx, Inc. CDNA · Entity 4344 | Tax withholdingCommon Stock | 19,832 | $79.26 | $1,571,884.32 |
DisclosureSEC source: 0001217234-21-000053 · wf-form4_161463427573853.xml · nonDerivative · entry 2 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 432,968 F3 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. F2 · balance_after: These shares remain subject to a lock-up agreement entered into among the Reporting Person and the representatives of the underwriters for the Issuer's public offering of common stock completed in January 2021. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:32 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-21-000053 · wf-form4_161463427573853.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 452,800 F1 · shares: The reported securities were represented by restricted performance stock units that were granted on February 3, 2020, 100% of which vested on February 25, 2021 upon the achievement of the requisite performance criteria. F2 · balance_after: These shares remain subject to a lock-up agreement entered into among the Reporting Person and the representatives of the underwriters for the Issuer's public offering of common stock completed in January 2021. Read SEC document |
| February 05, 2021 Filed Feb 6, 2021 00:21 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 44 | $92.15 | $4,054.60 |
DisclosureSEC source: 0001217234-21-000038 · wf-form4_161257088505727.xml · nonDerivative · entry 5 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412,800 F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 5, 2020. F2 · balance_after: These shares remain subject to a lock-up agreement entered into among the Reporting Person and the representatives of the underwriters for the Issuer's public offering of common stock completed in January 2021. Read SEC document |
| February 05, 2021 Filed Feb 6, 2021 00:21 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 657 | $91.53 | $60,137.18 |
DisclosureSEC source: 0001217234-21-000038 · wf-form4_161257088505727.xml · nonDerivative · entry 4 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412,844 F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 5, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.04 to $92.00, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. F2 · balance_after: These shares remain subject to a lock-up agreement entered into among the Reporting Person and the representatives of the underwriters for the Issuer's public offering of common stock completed in January 2021. Read SEC document |
| February 05, 2021 Filed Feb 6, 2021 00:21 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 1,316 | $90.36 | $118,914.15 |
DisclosureSEC source: 0001217234-21-000038 · wf-form4_161257088505727.xml · nonDerivative · entry 3 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 413,501 F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 5, 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.03 to $90.88, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. F2 · balance_after: These shares remain subject to a lock-up agreement entered into among the Reporting Person and the representatives of the underwriters for the Issuer's public offering of common stock completed in January 2021. Read SEC document |
| February 05, 2021 Filed Feb 6, 2021 00:21 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 7,983 | $89.58 | $715,084.41 |
DisclosureSEC source: 0001217234-21-000038 · wf-form4_161257088505727.xml · nonDerivative · entry 2 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 414,817 F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 5, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.00 to $89.97, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. F2 · balance_after: These shares remain subject to a lock-up agreement entered into among the Reporting Person and the representatives of the underwriters for the Issuer's public offering of common stock completed in January 2021. Read SEC document |
| February 03, 2021 Filed Feb 6, 2021 00:21 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantEmployee Stock Option (right to buy) · Derivative | 13,075 | $0.00 Strike: $87.37 | $0.00 |
DisclosureSEC source: 0001217234-21-000038 · wf-form4_161257088505727.xml · derivative · entry 8 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,075 Underlying: Common Stock · 13,075 shares Expires 2031-02-03 F8 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on February 3, 2022 and 1/48th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| February 03, 2021 Filed Feb 6, 2021 00:21 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 13,076 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-21-000038 · wf-form4_161257088505727.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 422,800 F1 · shares: The reported securities are represented by restricted stock units, 1/4th of which shall vest on February 3, 2022 and 1/4th of which shall vest on each anniversary thereafter. F2 · balance_after: These shares remain subject to a lock-up agreement entered into among the Reporting Person and the representatives of the underwriters for the Issuer's public offering of common stock completed in January 2021. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 22:34 UTC | CareDx, Inc. CDNA · Entity 4344 | Tax withholdingCommon Stock | 4,958 | $76.43 | $378,939.94 |
DisclosureSEC source: 0001217234-21-000028 · wf-form4_161230526537143.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,724 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of vested restricted stock units. F2 · balance_after: These shares remain subject to a lock-up agreement entered into among the Reporting Person and the representatives of the underwriters for the Issuer's public offering of common stock completed in January 2021. Read SEC document |
| January 27, 2021 Filed Jan 28, 2021 23:36 UTC | CareDx, Inc. CDNA · Entity 4344 | Tax withholdingCommon Stock | 2,231 | $74.62 | $166,477.22 |
DisclosureSEC source: 0001217234-21-000026 · wf-form4_161187698450768.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 414,682 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of vested restricted stock units. F2 · balance_after: These shares remain subject to a lock-up agreement entered into among the Reporting Person and the representatives of the underwriters for the Issuer's public offering of common stock completed in January 2021. Read SEC document |
| January 19, 2021 Filed Jan 22, 2021 02:03 UTC | CareDx, Inc. CDNA · Entity 4344 | Tax withholdingCommon Stock | 5,061 | $93.33 | $472,343.13 |
DisclosureSEC source: 0001217234-21-000022 · wf-form4_161128099878487.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416,913 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of vested restricted stock units. F2 · balance_after: These shares remain subject to a lock-up agreement entered into among the Reporting Person and the representatives of the underwriters for the Issuer's public offering of common stock completed in January 2021. Read SEC document |
| January 05, 2021 Filed Jan 6, 2021 23:01 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $6.31 | $0.00 |
DisclosureSEC source: 0001217234-21-000004 · wf-form4_160997407328903.xml · derivative · entry 6 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,140 Underlying: Common Stock · 10,000 shares Expires 2028-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on January 19, 2019 and 1/48th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| January 05, 2021 Filed Jan 6, 2021 23:01 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 2,826 | $72.36 | $204,502.92 |
DisclosureSEC source: 0001217234-21-000004 · wf-form4_160997407328903.xml · nonDerivative · entry 3 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,974 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.085 to $72.82, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| January 05, 2021 Filed Jan 6, 2021 23:01 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 7,174 | $71.75 | $514,734.50 |
DisclosureSEC source: 0001217234-21-000004 · wf-form4_160997407328903.xml · nonDerivative · entry 2 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,800 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.08 to $72.02, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.